Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia

被引：0
|
作者：
Tremblay, Gabriel
Bhor, Menaka
Roy, Anuja
Elliott, Brian
Dolph, Mike
Forsythe, Anna
Briggs, Andrew
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2146
引用
下载
收藏
页数：2
相关论文
共 27 条
  • [1] COST CONSEQUENCE MODEL COMPARING ELTROMBOPAG AND ROMIPLOSTIM FOR ADULT PATIENTS WITH PREVIOUSLY-TREATED CHRONIC IMMUNE THROMBOCYTOPENIA
    Tremblay, G.
    Dolph, M.
    Bhor, M.
    Elliott, B.
    VALUE IN HEALTH, 2017, 20 (05) : A220 - A220
  • [2] Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
    Tremblay, Gabriel
    Dolph, Mike
    Bhor, Menaka
    Said, Qayyim
    Roy, Anuja
    Elliott, Brian
    Briggs, Andrew
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 715 - 721
  • [3] Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
    Tremblay, Gabriel
    Dolph, Mike
    Bhor, Menaka
    Said, Qayyim
    Elliott, Brian
    Briggs, Andrew
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 705 - 713
  • [4] COST-CONSEQUENCE ANALYSIS COMPARING ROMIPLOSTIM TO RITUXIMAB IN THE TREATMENT OF ADULT PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN GERMANY
    von Depka, M.
    Salama, A.
    Perrin, A.
    Oelze, I.
    Chulikavit, M.
    Kunz, E.
    Kutikova, L.
    Thalheimer, M.
    HAEMATOLOGICA, 2012, 97 : 427 - 427
  • [5] COST-CONSEQUENCE ANALYSIS COMPARING ROMIPLOSTIM TO RITUXIMAB IN THE TREATMENT OF ADULT PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN FRANCE
    Chiche, L.
    Lefrere, F.
    Chulikavit, M.
    Perrin, A.
    Stern, L.
    Bischof, M.
    Cohen, S.
    VALUE IN HEALTH, 2011, 14 (07) : A415 - A415
  • [6] Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
    Patwardhan, Pallavi
    Proudman, David
    Allen, Jeffrey
    Lucas, Sedge
    Nellesen, Dave
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (10): : 1447 - 1456
  • [7] A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia
    Tomiyama, Y.
    Miyakawa, Y.
    Okamoto, S.
    Katsutani, S.
    Kimura, A.
    Okoshi, Y.
    Ninomiya, H.
    Kosugi, H.
    Nomura, S.
    Ozaki, K.
    Ikeda, Y.
    Hattori, T.
    Katsura, K.
    Kanakura, Y.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (05) : 799 - 806
  • [8] Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales
    Allen, Rachel
    Bryden, Peter
    Grotzinger, Kelly M.
    Stapelkamp, Ceilidh
    Woods, Bethan
    VALUE IN HEALTH, 2016, 19 (05) : 614 - 622
  • [9] Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag
    Tarantino, Michael D.
    Bakshi, Kalpana K.
    Brainsky, Andres
    PLATELETS, 2014, 25 (01) : 55 - 61
  • [10] Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim
    David J. Kuter
    Cynthia Macahilig
    Kelly M. Grotzinger
    Sara A. Poston
    Peter Feng Wang
    Katie L. Dawson
    Melea Ward
    International Journal of Hematology, 2015, 101 : 255 - 263
123